Shots:

• Orion to get right to commercialize CuraTeQ’s biosimilars in the Nordics, the Baltics, Austria, Hungary, and Slovenia. The products are currently in development or regulatory phases & are expected to be launched in Orion territories in 2023–2026, based on the achievement of the development and regulatory approvals
• The agreement will support Orion’s position in the Nordics and Baltics & helps to expand the accessibility of CuraTeQ’s biosimilar products in selected markets of the EU
• In 2020, the companies have entered into a license agreement, granting marketing and distribution rights for CuraTeQ's biosimilar products under development in the Nordic states, Austria, Hungary & Slovenia

­Ref: Orion | Image: Delsi Tech